Analysts Issue Forecasts for Moderna FY2029 Earnings

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for shares of Moderna in a research note issued on Monday, January 13th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of $22.02 per share for the year. The consensus estimate for Moderna's current full-year earnings is ($9.30) per share.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the prior year, the business posted ($1.39) earnings per share. Moderna's revenue was up 3.8% compared to the same quarter last year.

Several other research firms have also weighed in on MRNA. Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Berenberg Bank lifted their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday. UBS Group reduced their price target on shares of Moderna from $108.00 to $96.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Morgan Stanley decreased their target price on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research note on Wednesday. Finally, Barclays cut their target price on Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. Four research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $75.58.

Moderna Trading Down 2.9 %

Shares of MRNA stock traded down $1.01 during trading hours on Wednesday, reaching $33.76. The company had a trading volume of 7,323,516 shares, compared to its average volume of 12,449,448. Moderna has a 1-year low of $31.94 and a 1-year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a market cap of $12.99 billion, a price-to-earnings ratio of -5.80 and a beta of 1.60. The company has a 50 day moving average of $41.11 and a 200 day moving average of $67.32.

Institutional Investors Weigh In On Moderna

A number of hedge funds have recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC bought a new position in Moderna in the second quarter valued at about $26,000. MassMutual Private Wealth & Trust FSB boosted its position in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares during the period. Plato Investment Management Ltd boosted its position in Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock worth $49,000 after buying an additional 288 shares during the period. Blue Trust Inc. grew its holdings in Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company's stock worth $49,000 after acquiring an additional 574 shares during the last quarter. Finally, Larson Financial Group LLC increased its position in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after acquiring an additional 317 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 2,664 shares of company stock valued at $115,210 over the last quarter. 15.20% of the stock is owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.